65 related articles for article (PubMed ID: 18466967)
1. Screening for JAK2 V617F point mutation in patients with hypereosinophilic syndrome-in response to 'Hypereosinophilic syndrome: another face of janus?' by Dahabreh et al. published in Leukemia Research, in press.
Helbig G; Majewski M; Wieczorkiewicz A; Bober G; Grzegorczyk J; Dziaczkowska-Suszek J; Soja A; Bartkowska-Chrobok A; Krawczyk M; Krzemień S
Leuk Res; 2009 Mar; 33(3):e1-2. PubMed ID: 18466967
[No Abstract] [Full Text] [Related]
2. Hypereosinophilic syndrome: another face of janus?
Dahabreh IJ; Giannouli S; Zoi C; Zoi K; Loukopoulos D; Voulgarelis M
Leuk Res; 2008 Sep; 32(9):1483-5. PubMed ID: 18243306
[No Abstract] [Full Text] [Related]
3. The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.
Goulding C; Uttenthal B; Foroni L; Duke V; Traore A; Kottaridis P; Hoffbrand AV; Patch D; McNamara C
Int J Lab Hematol; 2008 Oct; 30(5):415-9. PubMed ID: 19046316
[TBL] [Abstract][Full Text] [Related]
4. Interferon alpha induces a good molecular response in a patient with chronic eosinophilic leukemia (CEL) carrying the JAK2V617F point mutation.
Helbig G; Stella-Holowiecka B; Majewski M; Lewandowska M; Holowiecki J
Haematologica; 2007 Nov; 92(11):e118-9. PubMed ID: 18024388
[TBL] [Abstract][Full Text] [Related]
5. Undiagnosed myeloproliferative disease in cases of intra-abdominal thrombosis: the utility of the JAK2 617F mutation.
P'ng S; Carnley B; Baker R; Kontorinis N; Cheng W
Clin Gastroenterol Hepatol; 2008 Apr; 6(4):472-5. PubMed ID: 18328792
[TBL] [Abstract][Full Text] [Related]
6. Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation.
Er TK; Lin SF; Chang JG; Hsieh LL; Lin SK; Wang LH; Lin CW; Chang CS; Liu TC
Clin Chim Acta; 2009 Oct; 408(1-2):39-44. PubMed ID: 19595684
[TBL] [Abstract][Full Text] [Related]
7. Isolated erythrocytosis in V617F negative patients with JAK2 exon 12 mutations: report of a new mutation.
Bernardi M; Ruggeri M; Albiero E; Madeo D; Rodeghiero F
Am J Hematol; 2009 Apr; 84(4):258-60. PubMed ID: 19229983
[No Abstract] [Full Text] [Related]
8. Severe asthma with blood hypereosinophilia associated with
Tabèze L; Marchand-Adam S; Borie R; Justet A; Dupin C; Dombret MC; Crestani B; Taillé C
Eur Respir J; 2019 Jun; 53(6):. PubMed ID: 31000675
[No Abstract] [Full Text] [Related]
9. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders.
Musolino C; Allegra A; Penna G; Centorrino R; Cuzzola M; D'Angelo A; Iacopino P; Alonci A
Acta Haematol; 2009; 122(1):46-9. PubMed ID: 19816006
[TBL] [Abstract][Full Text] [Related]
10. Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients.
Kouroupi E; Zoi K; Parquet N; Zoi C; Kiladjian JJ; Grigoraki V; Vainchenker W; Lellouche F; Marzac C; Schlageter MH; Dosquet C; Scott LM; Fenaux P; Loukopoulos D; Chomienne C; Cassinat B
Br J Haematol; 2008 Aug; 142(4):676-9. PubMed ID: 18503583
[No Abstract] [Full Text] [Related]
11. Absence of JAK2-V617F in paroxysmal nocturnal haemoglobinuria-associated thrombosis.
Fouassier M; Girodon F; Cleyrat C; Robillard N; Garand R; Hermouet S
Thromb Haemost; 2009 Jul; 102(1):180-2. PubMed ID: 19572087
[No Abstract] [Full Text] [Related]
12. Prevalence of the JAK2 V617F mutation in patients with unprovoked venous thromboembolism of common sites and without overt myeloproliferative neoplasms.
Za T; Fiorini A; Rossi E; Ciminello A; Chiusolo P; Leone G; De Stefano V
Br J Haematol; 2009 Mar; 144(6):965-7. PubMed ID: 19120368
[No Abstract] [Full Text] [Related]
13. The JAK2 V617F mutation is not a cause of central retinal vein occlusion.
Hermans C; Slachmuylder V; Gala JL; Lambert C; Detrait M
Thromb Haemost; 2008 Sep; 100(3):515-6. PubMed ID: 18766271
[No Abstract] [Full Text] [Related]
14. Presence of JAK2 V617F tyrosine kinase mutation as a myeloid-lineage-specific mutation in chronic neutrophilic leukaemia.
Lea NC; Lim Z; Westwood NB; Arno MJ; Gäken J; Mohamedali A; Mufti GJ
Leukemia; 2006 Jul; 20(7):1324-6. PubMed ID: 16673022
[No Abstract] [Full Text] [Related]
15. Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis.
Kreft A; Springer E; Lipka DB; Kirkpatrick CJ
Acta Haematol; 2009; 122(1):36-8. PubMed ID: 19713696
[TBL] [Abstract][Full Text] [Related]
16. BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T).
Gattenlohner S; Völker HU; Etschmann B; Einsele H; Müller-Hermelink HK
Am J Hematol; 2009 May; 84(5):306-7. PubMed ID: 18951468
[No Abstract] [Full Text] [Related]
17. The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemia.
Lambert JR; Gale RE; Linch DC
Br J Haematol; 2009 Apr; 145(1):128-30. PubMed ID: 19222478
[TBL] [Abstract][Full Text] [Related]
18. [Clinical study on relationship between protein tyrosine kinase JAK2 V617F mutation and high altitude polycythemia].
Ji LH; Li ZQ; Cui S
Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):319-20. PubMed ID: 22781728
[No Abstract] [Full Text] [Related]
19. No evidence for increased prevalence of JAK2 V617F in women with a history of recurrent miscarriage.
Dahabreh IJ; Jones AV; Voulgarelis M; Giannouli S; Zoi C; Alafakis-Tzannatos C; Varla-Leftherioti M; Moutsopoulos HM; Loukopoulos D; Fotiou S; Cross NC; Zoi K
Br J Haematol; 2009 Mar; 144(5):802-3. PubMed ID: 19036091
[No Abstract] [Full Text] [Related]
20. Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation.
Mercier F; Monczak Y; François M; Prchal J; Galipeau J
Exp Hematol; 2009 Mar; 37(3):416-20. PubMed ID: 19135773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
